Skip to main content
Erschienen in: Heart and Vessels 1/2017

22.04.2016 | Original Article

Significance of the percentage of cholesterol efflux capacity and total cholesterol efflux capacity in patients with or without coronary artery disease

verfasst von: Kenji Norimatsu, Takashi Kuwano, Shin-ichiro Miura, Tomohiko Shimizu, Yuhei Shiga, Yasunori Suematsu, Yuiko Miyase, Sen Adachi, Ayumi Nakamura, Satoshi Imaizumi, Atsushi Iwata, Hiroaki Nishikawa, Yoshinari Uehara, Keijiro Saku

Erschienen in: Heart and Vessels | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

We hypothesized that cholesterol efflux capacity is more useful than the lipid profile as a marker of the presence and the severity of coronary artery disease (CAD). Therefore, we investigated the associations between the presence and the severity of CAD and both the percentage of cholesterol efflux capacity and total cholesterol efflux capacity and the lipid profile including the high-density lipoprotein cholesterol (HDL-C) level in patients who underwent coronary computed tomography angiography (CTA). The subjects consisted of 204 patients who were clinically suspected to have CAD and underwent CTA. We isolated HDL from plasma by ultracentrifugation and measured the percentage of cholesterol efflux capacity using 3H-cholesterol-labeled J774 macrophage cells and calculated total cholesterol efflux capacity as follows: the percentage of cholesterol efflux capacity/100× HDL-C levels. While the percentage of cholesterol efflux capacity was not associated with the presence or the severity of CAD, total cholesterol efflux capacity and HDL-C in patients with CAD were significantly lower than those in patients without CAD. In addition, total cholesterol efflux capacity and HDL-C, but not the percentage of cholesterol efflux capacity, significantly decreased as the number of coronary arteries with significant stenosis increased. Total cholesterol efflux capacity was positively correlated with HDL-C, whereas the percentage of cholesterol efflux capacity showed only weak association. In a logistic regression analysis, the presence of CAD was independently associated with total cholesterol efflux capacity, in addition to age and gender. Finally, a receiver-operating characteristic curve analysis indicated that the areas under the curves for total cholesterol efflux capacity and HDL-C were similar. In conclusion, the percentage of cholesterol efflux capacity using the fixed amount of isolated HDL was not associated with CAD. On the other hand, the calculated total cholesterol efflux capacity that was dependent of HDL-C levels had a significant correlation with the presence of CAD.
Literatur
1.
Zurück zum Zitat Gordon DJ, Rifkind BM (1989) High-density lipoprotein—the clinical implications of recent studies. N Engl J Med 321:1311–1316CrossRefPubMed Gordon DJ, Rifkind BM (1989) High-density lipoprotein—the clinical implications of recent studies. N Engl J Med 321:1311–1316CrossRefPubMed
2.
Zurück zum Zitat Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC, Treating to New Targets Investigators (2007) HDL cholesterol very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357:1301–1310CrossRefPubMed Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC, Treating to New Targets Investigators (2007) HDL cholesterol very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357:1301–1310CrossRefPubMed
3.
Zurück zum Zitat Ogita M, Miyauchi K, Miyazaki T, Naito R, Konishi H, Tsuboi S, Dohi T, Kasai T, Yokoyama T, Okazaki S, Kurata T, Daida H (2014) Low high-density lipoprotein cholesterol is a residual risk factor associated with long-term clinical outcomes in diabetic patients with stable coronary artery disease who achieve optimal control of low-density lipoprotein cholesterol. Heart Vessels 29:35–41CrossRefPubMed Ogita M, Miyauchi K, Miyazaki T, Naito R, Konishi H, Tsuboi S, Dohi T, Kasai T, Yokoyama T, Okazaki S, Kurata T, Daida H (2014) Low high-density lipoprotein cholesterol is a residual risk factor associated with long-term clinical outcomes in diabetic patients with stable coronary artery disease who achieve optimal control of low-density lipoprotein cholesterol. Heart Vessels 29:35–41CrossRefPubMed
4.
Zurück zum Zitat Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR (1977) High density lipoprotein as a protective factor against coronary heart disease. The framingham study. Am J Med 62:707–714CrossRefPubMed Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR (1977) High density lipoprotein as a protective factor against coronary heart disease. The framingham study. Am J Med 62:707–714CrossRefPubMed
5.
Zurück zum Zitat AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W (2011) Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365:2255–2267 (Erratum, N Engl J Med 2012;367:189) AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W (2011) Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365:2255–2267 (Erratum, N Engl J Med 2012;367:189)
6.
Zurück zum Zitat Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B, Investigators ILLUMINATE (2007) Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357:2109–2122CrossRefPubMed Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B, Investigators ILLUMINATE (2007) Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357:2109–2122CrossRefPubMed
7.
Zurück zum Zitat Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS, dal-OUTCOMES Investigators (2012) Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367:2089–2099CrossRefPubMed Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS, dal-OUTCOMES Investigators (2012) Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367:2089–2099CrossRefPubMed
9.
Zurück zum Zitat Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ (2011) Cholesterol efflux capacity, highdensity lipoprotein function, and atherosclerosis. N Engl J Med 364:127–135CrossRefPubMedPubMedCentral Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ (2011) Cholesterol efflux capacity, highdensity lipoprotein function, and atherosclerosis. N Engl J Med 364:127–135CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Li XM, Tang WH, Mosior MK, Huang Y, Wu Y, Matter W, Gao V, Schmitt D, Didonato JA, Fisher EA, Smith JD, Hazen SL (2013) Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol 33:1696–1705CrossRefPubMedPubMedCentral Li XM, Tang WH, Mosior MK, Huang Y, Wu Y, Matter W, Gao V, Schmitt D, Didonato JA, Fisher EA, Smith JD, Hazen SL (2013) Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol 33:1696–1705CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Agarwala AP, Rodrigues A, Risman M, McCoy M, Trindade K, Qu L, Cuchel M, Billheimer J, Rader DJ (2015) High-density lipoprotein (HDL) phospholipid content and cholesterol efflux capacity are reduced in patients with very high HDL cholesterol and coronary disease. Arterioscler Thromb Vasc Biol 35:1515–1519CrossRefPubMedPubMedCentral Agarwala AP, Rodrigues A, Risman M, McCoy M, Trindade K, Qu L, Cuchel M, Billheimer J, Rader DJ (2015) High-density lipoprotein (HDL) phospholipid content and cholesterol efflux capacity are reduced in patients with very high HDL cholesterol and coronary disease. Arterioscler Thromb Vasc Biol 35:1515–1519CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, Neeland IJ, Yuhanna IS, Rader DR, de Lemos JA, Shaul PW (2014) HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 371:2383–2393CrossRefPubMedPubMedCentral Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, Neeland IJ, Yuhanna IS, Rader DR, de Lemos JA, Shaul PW (2014) HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 371:2383–2393CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Imaizumi S, Miura SI, Takata K, Takamiya Y, Kuwano T, Sugihara M, Ike A, Iwata A, Nishikawa H, Saku K (2015) Association between cholesterol efflux capacity and coronary restenosis after successful stent implantation. Heart Vessels. doi:10.1007/s00380-015-0738-1 Imaizumi S, Miura SI, Takata K, Takamiya Y, Kuwano T, Sugihara M, Ike A, Iwata A, Nishikawa H, Saku K (2015) Association between cholesterol efflux capacity and coronary restenosis after successful stent implantation. Heart Vessels. doi:10.​1007/​s00380-015-0738-1
14.
Zurück zum Zitat Annema W, Dikkers A, Freark de Boer J, Dullaart RP, Sanders JS, Bakker SJ, Tietge UJ (2016) HDL cholesterol efflux predicts graft failure in renal transplant recipients. J Am Soc Nephrol 27:595–603CrossRefPubMed Annema W, Dikkers A, Freark de Boer J, Dullaart RP, Sanders JS, Bakker SJ, Tietge UJ (2016) HDL cholesterol efflux predicts graft failure in renal transplant recipients. J Am Soc Nephrol 27:595–603CrossRefPubMed
15.
Zurück zum Zitat Singh N, Jacobs F, Rader DJ, Vanhaecke J, Van Cleemput J, De Geest B (2014) Impaired cholesterol efflux capacity and vasculoprotective function of high-density lipoprotein in heart transplant recipients. J Heart Lung Transplant 33:499–506CrossRefPubMed Singh N, Jacobs F, Rader DJ, Vanhaecke J, Van Cleemput J, De Geest B (2014) Impaired cholesterol efflux capacity and vasculoprotective function of high-density lipoprotein in heart transplant recipients. J Heart Lung Transplant 33:499–506CrossRefPubMed
16.
Zurück zum Zitat Mitsutake R, Niimura H, Miura S, Zhang B, Iwata A, Nishikawa H, Kawamura A, Kumagai K, Shirai K, Matsunaga A, Saku K (2006) Clinical significance of the coronary calcification score by multidetector row computed tomography for the evaluation of coronary stenosis in Japanese patients. Circ J 70:1122–1127CrossRefPubMed Mitsutake R, Niimura H, Miura S, Zhang B, Iwata A, Nishikawa H, Kawamura A, Kumagai K, Shirai K, Matsunaga A, Saku K (2006) Clinical significance of the coronary calcification score by multidetector row computed tomography for the evaluation of coronary stenosis in Japanese patients. Circ J 70:1122–1127CrossRefPubMed
17.
Zurück zum Zitat Dodge JT Jr, Brown BG, Bolson EL, Dodge HT (1988) Intrathoracic spatial location of coronary segments on the normal human heart. Circulation 78:1167–1180CrossRefPubMed Dodge JT Jr, Brown BG, Bolson EL, Dodge HT (1988) Intrathoracic spatial location of coronary segments on the normal human heart. Circulation 78:1167–1180CrossRefPubMed
18.
Zurück zum Zitat Koyoshi R, Miura S, Kumagai N, Shiga Y, Mitsutake R, Saku K (2012) Clinical significance of flow-mediated dilation, brachial intima-media thickness and pulse wave velocity in patients with and without coronary artery disease. Circ J 76:1469–1475CrossRefPubMed Koyoshi R, Miura S, Kumagai N, Shiga Y, Mitsutake R, Saku K (2012) Clinical significance of flow-mediated dilation, brachial intima-media thickness and pulse wave velocity in patients with and without coronary artery disease. Circ J 76:1469–1475CrossRefPubMed
19.
Zurück zum Zitat Rothblat GH, de la Llera-Moya M, Atger V, Kellner-Weibel G, Williams DL, Phillips MC (1999) Cell cholesterol efflux: integration of old and new observations provides new insights. J Lipid Res 40:781–796PubMed Rothblat GH, de la Llera-Moya M, Atger V, Kellner-Weibel G, Williams DL, Phillips MC (1999) Cell cholesterol efflux: integration of old and new observations provides new insights. J Lipid Res 40:781–796PubMed
20.
Zurück zum Zitat Takata K, Imaizumi S, Kawachi E, Suematsu Y, Shimizu T, Abe S, Matsuo Y, Tsukahara H, Noda K, Yahiro E, Zhang B, Uehara Y, Miura S, Saku K (2014) Impact of cigarette smoking cessation on high-density lipoprotein functionality. Circ J 78:2955–2962CrossRefPubMed Takata K, Imaizumi S, Kawachi E, Suematsu Y, Shimizu T, Abe S, Matsuo Y, Tsukahara H, Noda K, Yahiro E, Zhang B, Uehara Y, Miura S, Saku K (2014) Impact of cigarette smoking cessation on high-density lipoprotein functionality. Circ J 78:2955–2962CrossRefPubMed
21.
Zurück zum Zitat Ha JS, Ha CE, Chao JT, Petersen CE, Theriault A, Bhagavan NV (2003) Human serum albumin and its structural variants mediate cholesterol efflux from cultured endothelial cells. Biochim Biophys Acta 1640:119–128CrossRefPubMed Ha JS, Ha CE, Chao JT, Petersen CE, Theriault A, Bhagavan NV (2003) Human serum albumin and its structural variants mediate cholesterol efflux from cultured endothelial cells. Biochim Biophys Acta 1640:119–128CrossRefPubMed
22.
Zurück zum Zitat Toth PP (2005) High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies. Am J Cardiol 96:50K–58KCrossRefPubMed Toth PP (2005) High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies. Am J Cardiol 96:50K–58KCrossRefPubMed
23.
Zurück zum Zitat National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 106:3143–3421 National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 106:3143–3421
24.
Zurück zum Zitat Fournier N, de la Llera Moya M, Burkey BF, Swaney JB, Paterniti J Jr, Moatti N, Atger V, Rothblat GH (1996) The role of HDL phospholipids in efflux of cell cholesterol to whole serum: studies with human apoA-I transgenic rats. J Lipid Res 37:1704–1711PubMed Fournier N, de la Llera Moya M, Burkey BF, Swaney JB, Paterniti J Jr, Moatti N, Atger V, Rothblat GH (1996) The role of HDL phospholipids in efflux of cell cholesterol to whole serum: studies with human apoA-I transgenic rats. J Lipid Res 37:1704–1711PubMed
25.
Zurück zum Zitat Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura K, Saito S, Yamaguchi T, Daida H, Matsuzaki M (2009) Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 54:293–302CrossRefPubMed Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura K, Saito S, Yamaguchi T, Daida H, Matsuzaki M (2009) Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 54:293–302CrossRefPubMed
26.
Zurück zum Zitat Schoenhagen P, Tuzcu EM, Apperson-Hansen C, Wang C, Wolski K, Lin S, Sipahi I, Nicholls SJ, Magyar WA, Loyd A, Churchill T, Crowe T, Nissen SE (2006) Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the reversal of atherosclerosis with aggressive lipid lowering therapy (reversal) trial. Circulation 113:2826–2834CrossRefPubMed Schoenhagen P, Tuzcu EM, Apperson-Hansen C, Wang C, Wolski K, Lin S, Sipahi I, Nicholls SJ, Magyar WA, Loyd A, Churchill T, Crowe T, Nissen SE (2006) Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the reversal of atherosclerosis with aggressive lipid lowering therapy (reversal) trial. Circulation 113:2826–2834CrossRefPubMed
27.
Zurück zum Zitat Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, Raichlen JS, Uno K, Borgman M, Wolski K, Nissen SE (2011) Effect of two intensive statin regimens on progression of coronary disease. New Engl J Med 365:2078–2087CrossRefPubMed Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, Raichlen JS, Uno K, Borgman M, Wolski K, Nissen SE (2011) Effect of two intensive statin regimens on progression of coronary disease. New Engl J Med 365:2078–2087CrossRefPubMed
28.
Zurück zum Zitat Asztalos BF, Horvath KV, McNamara JR, Roheim PS, Rubinstein JJ, Schaefer EJ (2002) Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis 164:361–369CrossRefPubMed Asztalos BF, Horvath KV, McNamara JR, Roheim PS, Rubinstein JJ, Schaefer EJ (2002) Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis 164:361–369CrossRefPubMed
29.
Zurück zum Zitat Shimizu T, Miura S, Tanigawa H, Kuwano T, Zhang B, Uehara Y, Saku K (2014) Rosuvastatin activates ATP-binding cassette transporter A1-dependent efflux ex vivo and promotes reverse cholesterol transport in macrophage cells in mice fed a high-fat diet. Arterioscler Thromb Vasc Biol 34:2246–2253CrossRefPubMed Shimizu T, Miura S, Tanigawa H, Kuwano T, Zhang B, Uehara Y, Saku K (2014) Rosuvastatin activates ATP-binding cassette transporter A1-dependent efflux ex vivo and promotes reverse cholesterol transport in macrophage cells in mice fed a high-fat diet. Arterioscler Thromb Vasc Biol 34:2246–2253CrossRefPubMed
30.
Zurück zum Zitat Triolo M, Annema W, de Boer JF, Tietge UJ, Dullaart RP (2014) Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes. Eur J Clin Invest 44:240–248CrossRefPubMed Triolo M, Annema W, de Boer JF, Tietge UJ, Dullaart RP (2014) Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes. Eur J Clin Invest 44:240–248CrossRefPubMed
31.
Zurück zum Zitat Fine JJ, Hopkins CB, Ruff N, Newton FC (2006) Comparison of accuracy of 64-slice cardiovascular computed tomography with coronary angiography in patients with suspected coronary artery disease. Am J Cardiol 97:173–174CrossRefPubMed Fine JJ, Hopkins CB, Ruff N, Newton FC (2006) Comparison of accuracy of 64-slice cardiovascular computed tomography with coronary angiography in patients with suspected coronary artery disease. Am J Cardiol 97:173–174CrossRefPubMed
Metadaten
Titel
Significance of the percentage of cholesterol efflux capacity and total cholesterol efflux capacity in patients with or without coronary artery disease
verfasst von
Kenji Norimatsu
Takashi Kuwano
Shin-ichiro Miura
Tomohiko Shimizu
Yuhei Shiga
Yasunori Suematsu
Yuiko Miyase
Sen Adachi
Ayumi Nakamura
Satoshi Imaizumi
Atsushi Iwata
Hiroaki Nishikawa
Yoshinari Uehara
Keijiro Saku
Publikationsdatum
22.04.2016
Verlag
Springer Japan
Erschienen in
Heart and Vessels / Ausgabe 1/2017
Print ISSN: 0910-8327
Elektronische ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-016-0837-7

Weitere Artikel der Ausgabe 1/2017

Heart and Vessels 1/2017 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.